Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma

Authors

  • Olivia Beaudoux Department of Pathology, University Hospital of Reims, rue Koenig, FR-51100 Reims, France
  • Marine Ehret
  • Emilie Criquet
  • Joséphine Franceschi
  • Anne Durlach
  • Anne Durlach
  • Jean-Baptiste Oudart
  • Laetitia Visseaux
  • Florent Grange

DOI:

https://doi.org/10.2340/00015555-3715

Keywords:

penile melanoma, mucosal melanoma, KIT inhibitor, KIT mutation

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Sánchez-Ortiz R, Huang SF, Tamboli P, Prieto VG, Hester G, Pettaway CA. Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol 2005; 173: 1958-1965.

DOI: https://doi.org/10.1097/01.ju.0000159207.91737.53

Mignard C, Deschamps Huvier A, Gillibert A, Duval Modeste AB, Dutriaux C, Khammari A, et al. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma. J Oncol 2018; 2018: 1908065.

DOI: https://doi.org/10.1155/2018/1908065

Nassar KW, Tan AC. The mutational landscape of mucosal melanoma. Semin Cancer Biol 2020; 61: 139-148.

DOI: https://doi.org/10.1016/j.semcancer.2019.09.013

Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, et al. STAT3 mediates nilotinib response in KIT-altered melanoma: a phase II multicenter trial of the French skin cancer network. J Invest Dermatol 2018; 138: 58-67.

DOI: https://doi.org/10.1016/j.jid.2017.07.839

Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman R-A, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305: 2327-2334.

DOI: https://doi.org/10.1001/jama.2011.746

Griewank KG, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res Off J Am Assoc Cancer Res 2013; 19: 3143-3152.

DOI: https://doi.org/10.1158/1078-0432.CCR-13-0163

Omholt K, Grafström E, Kanter-Lewensohn L, Hansson J, Ragnarsson-Olding BK. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res Off J Am Assoc Cancer Res 2011; 17: 3933-3942.

DOI: https://doi.org/10.1158/1078-0432.CCR-10-2917

Saint-Jean M, Fronteau C, Peuvrel L, Khammari A, Varey E, Quéreux G, et al. Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients. Medicine (Baltimore) 2020; 99: e21329.

DOI: https://doi.org/10.1097/MD.0000000000021329

Downloads

Published

2021-04-12

How to Cite

Beaudoux, O., Ehret, M., Criquet, E., Franceschi, J., Durlach, A., Durlach, A., Oudart, J.-B., Visseaux, L., & Grange, F. (2021). Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma . Acta Dermato-Venereologica, 101(4), adv00426. https://doi.org/10.2340/00015555-3715

Issue

Vol. 101 No. 4 (2021): April

Section

Short Communication

Categories

License

Copyright (c) 2021 Olivia Beaudoux, Marine Ehret, Emilie Criquet, Joséphine Franceschi, Anne Durlach, Anne Durlach, Jean-Baptiste Oudart, Laetitia Visseaux, Florent Grange

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC